April 2019 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2018/19 Invitation to Tender, dated 1 November 2018.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Clindamycin |
Inj phosphate 150 mg per ml, 4 ml ampoule, 10 ampoule pack |
$65.00 |
$39.00 |
Dalacin C |
1 July 2019 |
1 October 2019 |
|
Levomepromazine maleate |
Tab 25 mg, 100 tablet, blister pack |
$16.93 |
$16.10 |
Nozinan |
1 June 2019 |
1 September 2019 |
|
Levomepromazine maleate |
Tab 100 mg, 100 tablet, blister pack |
$43.96 |
$41.75 |
Nozinan |
1 June 2019 |
1 September 2019 |
|
Omeprazole |
Inj 40 mg ampoule with diluent, 5 glass ampoule pack |
$33.98 |
$33.98 |
Dr Reddy’s Omeprazole |
1 July 2019 |
1 October |
|
Roxithromycin |
Tab 150 mg, 50 tablet, blister pack |
$7.48 |
$8.28 |
Arrow-Roxithromycin |
1 June 2019 |
1 September 2019 |
|
Roxithromycin |
Tab 300 mg, 50 tablet, blister pack |
$14.40 |
$16.33 |
Arrow-Roxithromycin |
1 June 2019 |
1 September 2019 |
|
Zoledronic acid |
Inj 0.05 mg per ml, 100 ml, vial, |
$600.00 |
$60.00 |
Aclasta |
1 July 2019 |
1 October 2019 |
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Sole supply brand (Supplier) |
Listing date |
Sole Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Amiodarone hydrochloride |
Tab 100 mg, 30 tablet, blister pack |
$4.66 |
$3.80 |
Aratac |
1 July 2019 |
1 December 2019 |
Cordarone-X |
|
Amiodarone hydrochloride |
Tab 200 mg, 30 tablet, blister pack |
$7.63 |
$5.25 |
Aratac |
1 July 2019 |
1 December 2019 |
Cordarone-X |
|
Cetomacrogol with glycerol |
Crm 90% with glycerol 10%, 1,000 ml OP, bottle pack |
$3.87 |
$3.10 |
Boucher |
1 October 2019 |
1 March 2020 |
Pharmacy Health Sorbolene with Glycerin |
|
Cetomacrogol with glycerol |
Crm 90% with glycerol 10%, 500 ml OP, bottle pack |
$2.82 |
$2.35 |
Boucher |
1 October 2019 |
1 March 2020 |
Pharmacy Health Sorbolene with Glycerin |
|
Clindamycin |
Cap hydrochloride 150 mg, 24 capsule, blister pack |
$4.10 |
$4.61 (24 pack) |
Dalacin C |
1 November 2019 |
1 April 2020 |
Clindamycin ABM |
|
Clopidogrel |
Tab 75 mg, 84 tablet, blister pack |
$5.44 |
$4.60 |
Clopidogrel Multichem (Multichem) |
1 December 2019 |
1 May 2020 |
Arrow - Clopid |
|
Levomepromazine hydrochloride |
Inj 25 mg per ml, 1 ml ampoule, 10 ampoule pack |
$47.89 |
$33.50 |
Nozinan |
1 November 2019 |
1 April 2020 |
Wockhardt |
|
Lidocaine [lignocaine] |
Gel 2%, 10 ml urethral syringe, 25 prefilled syringe pack |
$160.00 |
$105.00 |
Cathejell |
1 June 2019 |
1 November 2019 |
Pfizer (10 pack) |
|
Ondansetron |
Tab 4 mg, 50 tablet, blister pack |
$3.36 |
$2.68 |
Onrex |
1 November 2019 |
1 April 2020 |
Apo-Ondansetron |
|
Ondansetron |
Tab 8 mg, 50 tablet, blister pack |
$4.77 |
$4.57 |
Onrex |
1 November 2019 |
1 April 2020 |
Apo-Ondansetron |
|
Sodium chloride |
Inj 0.9%, 5 ml ampoule, |
$7.00 |
$2.80 (20 pack) |
Fresenius Kabi |
1 July 2019 |
1 December 2019 |
InterPharma Multichem |
|
Sodium chloride |
Inj 0.9%, 10 ml ampoule, |
$6.63 |
$5.40 |
Fresenius Kabi |
1 July 2019 |
1 December 2019 |
Pfizer |
|
Sodium chloride |
Inj 0.9%, 20 ml ampoule, |
$7.50 $5.00 |
$5.00 (20 pack) |
Fresenius Kabi |
1 July 2019 |
1 December 2019 |
InterPharma (30 pack) Multichem (20 pack) |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Cetomacrogol with glycerol |
Crm 90% with glycerol 10%, 100 g tube |
$3.20 |
$1.65 |
healthE |
1%* |
1 September 2019 |
1 December 2019 |
|
Clindamycin |
Inj phosphate 150 mg per ml, 4 ml ampoule, 10 ampoule pack |
$65.00 |
$39.00 |
Dalacin C |
1% |
1 July 2019 |
1 October 2019 |
|
Omeprazole |
Inj 40 mg ampoule with diluent, 5 glass ampoule pack |
$33.98 |
$33.98 |
Dr Reddy’s Omeprazole (Dr Reddy’s) |
1% |
1 July 2019 |
1 October |
|
Roxithromycin |
Tab 150 mg, 50 tablet, blister pack |
$7.48 |
$8.28 |
Arrow-Roxithromycin |
1% |
1 June 2019 |
1 September 2019 |
|
Roxithromycin |
Tab 300 mg, 50 tablet, blister pack |
$14.40 |
$16.33 |
Arrow-Roxithromycin |
1% |
1 June 2019 |
1 September 2019 |
|
Voriconazole1 |
Inj 200 mg vial, 1 vial pack |
$65.00 |
$44.00 |
Neo Health |
1% |
1 July 2019 |
1 October 2019 |
|
Zoledronic acid |
Inj 5 mg per 100 ml, vial, 1 vial pack |
$600.00 |
$60.00 |
Aclasta |
1% |
1 July 2019 |
1 October 2019 |
|
* The DV Limit applies to the pack sizes of 100 g or less. 1 The listed brand name of this product will be amended from Generic Partners to Neo Health. |
|||||||
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current price |
New pack price |
Hospital supply brand (Supplier) |
DV |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Amiodarone hydrochloride |
Tab 100 mg, 30 tablet, blister pack |
$4.66 |
$3.80 |
Aratac |
1% |
1 July 2019 |
1 December 2019 |
Cordarone-X |
|
Amiodarone hydrochloride |
Tab 200 mg, 30 tablet, blister pack |
$7.63 |
$5.25 |
Aratac |
1% |
1 July 2019 |
1 December 2019 |
Cordarone-X |
|
Cetomacrogol with glycerol |
Crm 90% with glycerol 10%, 1,000 ml, bottle pack |
$3.87 |
$3.10 |
Boucher |
1%* |
1 October 2019 |
1 March 2020 |
Pharmacy Health Sorbolene with Glycerin |
|
Cetomacrogol with glycerol |
Crm 90% with glycerol 10%, 500 ml, bottle pack |
$2.82 |
$2.35 |
Boucher |
1%* |
1 October 2019 |
1 March 2020 |
Pharmacy Health Sorbolene with Glycerin |
|
Clindamycin |
Cap hydrochloride 150 mg, 24 capsule, blister pack |
$4.10 |
$4.61 |
Dalacin C |
1% |
1 November 2019 |
1 April 2020 |
Clindamycin ABM |
|
Clopidogrel |
Tab 75 mg, 84 tablet, blister pack |
$5.44 |
$4.60 |
Clopidogrel Multichem (Multichem) |
1% |
1 December 2019 |
1 May 2020 |
Arrow - Clopid |
|
Levomepromazine hydrochloride |
Inj 25 mg per ml, 1 ml ampoule, 10 ampoule pack |
$47.89 |
$33.50 |
Nozinan |
1% |
1 November 2019 |
1 April 2020 |
Wockhardt |
|
Lidocaine [lignocaine] hydrochloride |
Gel 2%, 10 ml urethral syringe, 25 prefilled syringe pack |
$160.00 |
$105.00 |
Cathejell |
1% |
1 June 2019 |
1 November 2019 |
Pfizer (10 pack) |
|
Ondansetron |
Tab 4 mg, 50 tablet, blister pack |
$3.36 |
$2.68 |
Onrex |
1% |
1 November 2019 |
1 April 2020 |
Apo-Ondansetron |
|
Ondansetron |
Tab 8 mg, 50 tablet, blister pack |
$4.77 |
$4.57 |
Onrex |
1% |
1 November 2019 |
1 April 2020 |
Apo-Ondansetron |
|
Sodium chloride |
Inj 0.9%, 5 ml ampoule, |
$7.00 |
$2.80 |
Fresenius Kabi |
1% |
1 July 2019 |
1 December 2019 |
InterPharma |
|
Sodium chloride |
Inj 0.9%, 10 ml ampoule, |
$6.63 |
$5.40 |
Fresenius Kabi |
1% |
1 July 2019 |
1 December 2019 |
Pfizer |
|
Sodium chloride |
Inj 0.9%, 20 ml ampoule, |
$7.50 (30 pack) |
$5.00 |
Fresenius Kabi |
1% |
1 July 2019 |
1 December 2019 |
InterPharma (30 pack) Multichem (20 pack) |
|
* DV Limit applies to pack sizes of greater than 100 g. |
||||||||
5. Tenders awarded to pharmaceuticals where no brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|
|
Levomepromazine |
Tab 25 mg, 100 tablet, blister pack |
$16.10 |
Nozinan |
1% |
1 June 2019 |
1 September 2019 |
|
Levomepromazine |
Tab 100 mg, 100 tablet, blister pack |
$41.75 |
Nozinan |
1% |
1 June 2019 |
1 September 2019 |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2017/18 Invitation to Tender, dated 2 November 2017 and the 2018/19 Invitation to Tender, dated 1 November 2018.
2017/18 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Metaraminol tartrate |
Inj 1 mg per ml, 1 ml |
2018/19 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Albendazole |
Tab |
|
Amiloride with hydrochlorothiazide |
Tab 5 mg with hydrochlorothiazide 50 mg |
|
Benzoyl peroxide |
Soln/Gel/Cream/Lotion 5% |
|
Betaxolol hydrochloride |
Eye drops 0.25% |
|
Betaxolol hydrochloride |
Eye drops 0.5% |
|
Busulfan |
Inj 6 mg per ml |
|
Busulfan |
Tab 2 mg |
|
Caspofungin [whole market] |
Inj 50 mg |
|
Cefotaxime |
Inj 500 mg |
|
Chlorpromazine hydrochloride |
Oral liq 100 mg per 5 ml |
|
Dextrochlorpheniramine maleate |
Oral liq 2 mg per 5 ml |
|
Dextrochlorpheniramine maleate |
Tab 2 mg |
|
Diclofenac sodium |
Tab 50 mg dispersible |
|
Digoxin |
Inj 250 mcg per ml, 2 ml |
|
Doxycycline |
Tab 20 mg - 50 mg |
|
Haloperidol decanoate |
Inj 50 mg per ml, 1 ml ampoule |
|
Hydrogen peroxide |
Soln 3% (10 vol) |
|
Imipramine hydrochloride |
Tab 10 mg |
|
Imipramine hydrochloride |
Tab 25 mg |
|
Lorazepam |
Inj 4 mg per ml, 1 ml |
|
Magnesium Salt |
Tab |
|
Mexiletine |
Cap 150 mg |
|
Mexiletine |
Cap 250 mg |
|
Morphine sulphate |
Tab long-acting 10 mg |
|
Morphine sulphate |
Tab long-acting 100 mg |
|
Morphine sulphate |
Tab long-acting 30 mg |
|
Morphine sulphate |
Tab long-acting 60 mg |
|
Nitazoxanide |
Tab 500 mg |
|
Nystatin |
Cap 500,000 u |
|
Nystatin |
Crm 100,000 u per g |
|
Nystatin |
Tab 500,000 u |
|
Paper wasp venom |
Inj 550 mcg vial with diluent |
|
Paper wasp venom |
Treatment kit - 6 vials 120 mcg freeze dried venom, |
|
Pimozide |
Tab 2 mg or less |
|
Pimozide |
Tab 4 mg or more |
|
Primidone |
Tab 25 mg |
|
Primidone |
Tab 50 mg |
|
Simeticone |
Oral drops 100 mcg per ml |
|
Sodium hyaluronate [hyaluronic acid] |
Inj 30 mg per ml with chondroitin sulphate 40 mg per |
|
Sodium hyaluronate [hyaluronic acid] |
Inj 30 mg per ml with chondroitin sulphate 40 mg per |
|
Sucralfate |
Tab 1 g |
|
Tetracycline |
Cap 500 mg |
|
Tetracycline |
Tab 250 mg |
|
Tobramycin |
Eye drops 0.3% |
|
Triazolam |
Tab 125 mcg |
|
Triazolam |
Tab 250 mcg |
|
Zinc |
Oral liq 5 mg per 5 drops |
|
Zuclopenthixol acetate |
Inj 50mg per ml, 2 ml |
For products included in the 2016/17, 2017/18 and 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.